R. Kent McGaughy Net Worth

The estimated Net Worth of R Kent Jr Mc Gaughy is at least 371 百万$ dollars as of 15 October 2021. Mr. Gaughy owns over 683,871 units of Reata Pharmaceuticals Inc stock worth over 370,782,383$ and over the last 8 years he sold RETA stock worth over 0$. In addition, he makes 569,676$ as Independent Director at Reata Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. McGaughy RETA stock SEC Form 4 insiders trading

R has made over 22 trades of the Reata Pharmaceuticals Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 683,871 units of RETA stock worth 5,300,000$ on 15 October 2021.

The largest trade he's ever made was buying 1,780,000 units of Reata Pharmaceuticals Inc stock on 17 July 2020 worth over 2,225,000$. On average, R trades about 117,363 units every 46 days since 2016. As of 15 October 2021 he still owns at least 2,151,209 units of Reata Pharmaceuticals Inc stock.

You can see the complete history of Mr. Gaughy stock trades at the bottom of the page.

R. Kent McGaughy biography

R. Kent McGaughy Jr. serves as Independent Director of the Company. Prior to joining CPMG’s predecessor, Cardinal Investment Company, Inc., in 1997, he worked in mergers and acquisitions at Simmons & Company International. He currently serves on the boards of Apollo Endosurgery, Inc., a publicly-traded company, and several private companies. Mr. McGaughy, Jr. received his B.A. from The University of Texas (summa cum laude and member of Phi Beta Kappa) and his M.B.A. from Harvard Business School. Our Board believes that Mr. McGaughy, Jr. is qualified to serve on our Board due to his extensive experience investing and extensive service on the boards of directors of other companies.

What is the salary of R McGaughy?

As the Independent Director of Reata Pharmaceuticals Inc, the total compensation of R McGaughy at Reata Pharmaceuticals Inc is 569,676$. There are 13 executives at Reata Pharmaceuticals Inc getting paid more, with Manmeet Soni having the highest compensation of 12,612,200$.

How old is R McGaughy?

R McGaughy is 48, he's been the Independent Director of Reata Pharmaceuticals Inc since 2004. There are 10 older and 5 younger executives at Reata Pharmaceuticals Inc. The oldest executive at Reata Pharmaceuticals Inc is Michael D. Wortley, 73, who is the Exec. VP & Chief Legal Officer.

What's R McGaughy's mailing address?

R's mailing address filed with the SEC is 2000 McKinney Ave, Dallas, TX 75201, USA.

Insiders trading at Reata Pharmaceuticals Inc

Over the last 8 years, insiders at Reata Pharmaceuticals Inc have traded over 176,850,875$ worth of Reata Pharmaceuticals Inc stock and bought 8,443,489 units worth 179,313,590$ . The most active insiders traders include Holdings A/S Novo、R Kent Jr Mc Gaughy、Inc Cpmg. On average, Reata Pharmaceuticals Inc executives and independent directors trade stock every 16 days with the average trade being worth of 10,950,893$. The most recent stock trade was executed by Andrea Loewen on 14 September 2023, trading 3,175 units of RETA stock currently worth 546,195$.

What does Reata Pharmaceuticals Inc do?

reata pharmaceuticals, inc. (nasdaq:reta) is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. reata’s two most advanced clinical candidates, bardoxolone methyl and omaveloxolone, target the important transcription factor nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.

Complete history of Mr. Gaughy stock trades at Apollo Endosurgery Inc、Reata Pharmaceuticals Inc

Reata Pharmaceuticals Inc executives and stock owners

Reata Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Manmeet Soni,
  Chief Financial Officer, Chief Operating Officer, Executive Vice President
• J. Warren Huff,
  Chairman of the Board, President, Chief Executive Officer
• Colin Meyer,
  Executive Vice President, Chief Research and Development Officer
• Michael Wortley,
  Executive Vice President, Chief Legal Officer
• Dawn Bir,
  Executive Vice President, Chief Commercial Officer
• Manmeet Singh Soni,
  COO, CFO & Pres
• J. Warren Huff,
  Chairman & CEO
• Dr. Colin J. Meyer M.D.,
  Exec. VP & Chief Innovation Officer
• Michael D. Wortley,
  Exec. VP & Chief Legal Officer
• Dawn Carter Bir,
  Exec. VP & Chief Commercial Officer
• Jack Nielsen,
  Independent Director
• William McClellan,
  Independent Director
• William Rose,
  Independent Director
• R. Kent McGaughy,
  Independent Director
• Vineet Jindal,
  Vice President, Corporate Communications and Strategy
• Martin Edwards,
  Independent Director
• Seemi Khan,
  Chief Medical Officer
• Andrea Loewen,
  Vice President - Global Regulatory Affairs
• Kevin Johnston,
  Chief Technical Officer, Vice President
• Steve Harman,
  VP & Chief HR Officer
• Dakota Gallivan,
  VP & Chief Healthcare Compliance Officer
• Dr. W. Christian Wigley Ph.D.,
  Sr. VP & Chief Scientific Officer
• Bhaskar Anand,
  VP & Chief Accounting Officer
• William Puffin Partners, L....,
  
• Dennis K. Stone,
  Director
• Elaine Castellanos,
  VP, Chief Accounting Officer
• Holdings A/S Novo,
  10% owner
• James Edward Bass,
  Director
• James W Jr Traweek,
  
• Inc Cpmg,
  
• Inc. Abb Vie,
  10% owner
• Keith Wayne Ward,
  See Remarks
• William Rose Evelyn P.Edwar...,
  
• William Puffin Partners, L....,
  
• Antal Rohit Cpmg Inc Desai,
  
• William Montrose Investment...,
  
• William Charles Henry Rose ...,
  
• William Puffin Partners, L....,
  
• William Estate Of Edward W....,
  
• Jason Douglas Wilson,
  Executive VP of Operations
• Pharma Llcstapleton Craig R...,
  
• Christy J. Oliger,
  Director
• Shamim Ruff,
  Director
• Bhaskar Anand,
  SVP, Chief Accounting Officer
• Steven Ryder,
  Director
• Samina Khan,
  SVP, Chief Medical Officer
• Rajiv Patni,
  EVP, Chief R&D Officer